PMID- 29424776
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20240416
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 32
IP  - 7
DP  - 2018 Apr 24
TI  - A prospective study of serum microbial translocation biomarkers and risk of 
      AIDS-related non-Hodgkin lymphoma.
PG  - 945-954
LID - 10.1097/QAD.0000000000001771 [doi]
AB  - BACKGROUND: Chronic immune activation is a harbinger of AIDS-associated 
      non-Hodgkin lymphoma (AIDS-NHL), yet the underlying basis is unclear. Microbial 
      translocation, the passage of microbial components from the gastrointestinal 
      tract into the systemic circulation, is a source of systemic immune activation in 
      HIV infection and may be an important contributor to chronic B-cell activation 
      and subsequent AIDS-NHL development. METHOD: We measured biomarkers of microbial 
      translocation including bacterial receptors/antibodies, intestinal barrier 
      proteins, and macrophage activation-associated cytokines/chemokines, in serum 
      from 200 HIV-infected men from the Multicenter AIDS Cohort Study prior to their 
      AIDS-NHL diagnosis (mean = 3.9 years; SD = 1.6 years) and 200 controls. Controls 
      were HIV-infected men who did not develop AIDS-NHL, individually matched to cases 
      on CD4 T-cell count, prior antiretroviral drug use, and recruitment year into the 
      cohort. RESULTS: Biomarkers of bacterial translocation and intestinal 
      permeability were significantly increased prior to AIDS-NHL. 
      Lipopolysaccharide-binding protein (LPB), fatty acid-binding protein 2 (FABP2), 
      and soluble CD14 were associated with 1.6-fold, 2.9-fold, and 3.7-fold increases 
      in AIDS-NHL risk for each unit increase on the natural log scale, respectively. 
      Haptoglobin had a 2.1-fold increase and endotoxin-core antibody a 2.0-fold 
      decrease risk for AIDS-NHL (fourth versus first quartile). Biomarkers of 
      macrophage activation were significantly increased prior to AIDS-NHL: B-cell 
      activation factor (BAFF), IL18, monocyote chemoattractant protein-1 (MCP1), tumor 
      necrosis factor-alpha (TNFalpha), and CCL17 had 2.2-fold, 2.0-fold, 1.6-fold, 2.8-fold, 
      and 1.7-fold increases in risk for each unit increase on the natural log scale, 
      respectively. CONCLUSION: These data provide evidence for microbial translocation 
      as a cause of the systemic immune activation in chronic HIV infection preceding 
      AIDS-NHL development.
FAU - Epeldegui, Marta
AU  - Epeldegui M
AD  - University of California, Los Angeles, California.
FAU - Magpantay, Larry
AU  - Magpantay L
AD  - University of California, Los Angeles, California.
FAU - Guo, Yu
AU  - Guo Y
AD  - University of California, Los Angeles, California.
FAU - Halec, Gordana
AU  - Halec G
AD  - University of California, Los Angeles, California.
FAU - Cumberland, William G
AU  - Cumberland WG
AD  - University of California, Los Angeles, California.
FAU - Yen, Priscilla K
AU  - Yen PK
AD  - University of California, Los Angeles, California.
FAU - Macatangay, Bernard
AU  - Macatangay B
AD  - University of Pittsburg School of Medicine, Pittsburgh, Pennsylvania.
FAU - Margolick, Joseph B
AU  - Margolick JB
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
FAU - Rositch, Anne F
AU  - Rositch AF
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
FAU - Wolinsky, Steven
AU  - Wolinsky S
AD  - Northwestern University Feinberg School of Medicine, Chicago, Ilinois.
FAU - Martinez-Maza, Otoniel
AU  - Martinez-Maza O
AD  - University of California, Los Angeles, California.
FAU - Hussain, Shehnaz K
AU  - Hussain SK
AD  - Cedars-Sinai Medical Center, Los Angeles, California, USA.
LA  - eng
GR  - U01 AI035042/AI/NIAID NIH HHS/United States
GR  - HHSN261201000140C/CA/NCI NIH HHS/United States
GR  - R21 CA220475/CA/NCI NIH HHS/United States
GR  - UL1 TR001079/TR/NCATS NIH HHS/United States
GR  - R01 CA168482/CA/NCI NIH HHS/United States
GR  - U01 AI035041/AI/NIAID NIH HHS/United States
GR  - U58 DP000795/DP/NCCDPHP CDC HHS/United States
GR  - HHSN261201000035I/CA/NCI NIH HHS/United States
GR  - U58 DP003862/DP/NCCDPHP CDC HHS/United States
GR  - U01 AI035040/AI/NIAID NIH HHS/United States
GR  - U01 AI035039/AI/NIAID NIH HHS/United States
GR  - P30 CA016042/CA/NCI NIH HHS/United States
GR  - UM1 AI035043/AI/NIAID NIH HHS/United States
GR  - P30 AI028697/AI/NIAID NIH HHS/United States
GR  - HHSN261201000035C/PC/NCI NIH HHS/United States
GR  - HHSN261201000034C/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Biomarkers)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - *Bacterial Translocation
MH  - Biomarkers/*blood
MH  - HIV Infections/*complications
MH  - Humans
MH  - Immunologic Factors/*blood
MH  - *Lymphocyte Activation
MH  - Lymphoma, Non-Hodgkin/*epidemiology
MH  - Macrophage Activation
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Serum/*chemistry
MH  - Young Adult
PMC - PMC5869109
MID - NIHMS939285
COIS- Conflict-of-interest disclosure: All authors declare no competing financial 
      interests.
EDAT- 2018/02/10 06:00
MHDA- 2019/09/20 06:00
PMCR- 2019/04/24
CRDT- 2018/02/10 06:00
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2019/04/24 00:00 [pmc-release]
AID - 10.1097/QAD.0000000000001771 [doi]
PST - ppublish
SO  - AIDS. 2018 Apr 24;32(7):945-954. doi: 10.1097/QAD.0000000000001771.